High Quality Peptide Cjc-1295 Without Dac Cjc-1295 No Dac
Modified Growth Releasing Factor aminos 1-29, usually referred to as Modified GRF (1-29) or “ModGRF(1-29),” also known as CJC-1295 without DAC, is a synthetic analog of the endogenous peptide signaling hormone Growth Hormone Releasing Hormone (GHRH). Endogenously produced GHRH has 44 amino acids in its chain structure. A truncated synthetic form of GHRH called Sermorelin or GRF 1-29 has 29 amino acids; Modified GRF (1-29) is further changed in that it has four substituted aminos in its chain that serve the purposes of preventing degradation and oxidation in manufacture and transport as well as in vivo, while also increasing binding affinity to the GHRH receptors.
Modified GRF (1-29) is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation.
Cjc-1295 Without Dac Specifications：
Cjc-1295 Without Dac
Loss on Drying
Acetate Content (HPIC)
Peptide Content (N%)
Amino Acid Composition
卤10% of theoretical
Single Impurity (HPLC)
How about the dosage?
adult 30 ug/kg of CJC-1295 given weekly
Suggestion:please use it with the doctor's instructions.
What is cjc-1295?
1. Cjc-1295 is also referred to as Mod GRF 1-29, which in most cases is recommended to exceed CJC-1295. The duration of the effect of the product is different. MOD GRF shortens the desired duration of the drug, and CJC-1295 has the effect of preventing the prolongation of the duration of such effects. 2.CJC-1295, also known as DAC: GRF (short for drug affinity complex) is a synthetic analogue of hormone releasing hormone (GHRH) (also known as growth hormone releasing factor (GRF)) and hormone GHS), which was developed by ConjuChem Biotechnologies. It is an improvement with improved pharmacokinetics, particularly with regard to half-life of GHRH (1-29). CJC-1295 has been shown to prolong the half-life and bioavailability of somatotropin-releasing hormone 1-29. It increases the half-life of the agent by bioconjugation.
What's the usage?
1.enhances protein production in the body
2.boosts muscle mass
3.induces lipolysis - the breakdown of fat tissue
4.boosts recovery from injuries
5.increases bone density
6.reduces aging factors like skin wrinkles
7.stimulate cell growth
8.treat withered tissue or organs
What should be noticed?
1.Since CJC-1295 is just a peptide and not a steroid, it has very minimal side effects. People using high doses of this peptide can experience mild side effects like long dreams that they can remember clearly, hands and fingers going numb, dull aches in the joints, and weakness as well as lightheadedness if enough carbohydrates are not consumed.
2.Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.
Main Export Market:
Our Product Range: